Parabilis Medicines (PBLS) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.47 billion vs $3.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBLS | TARS |
|---|---|---|
| Share price | $28.09 | $72.22 |
| Market cap | $3.47B | $3.38B |
| 1-day change | -2.53% | -1.89% |
| YTD return | — | -11.80% |
| 1-year return | — | +3.54% |
| 5-year return | — | +153.23% |
| EPS (TTM) | $-9.51 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | — | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $42.49 | $91.53 |
| 52-week low | $24.51 | $53.89 |
| Distance from 52-week high | -33.89% | -21.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +48.63% | +37.77% |
| Average volume | 690.91K | 894.35K |
| Shares outstanding | 121.95M | 46.79M |
| Employees | 145 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
PBLS vs TARS FAQ
Which is bigger, Parabilis Medicines or Tarsus Pharmaceuticals?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.47B compared with $3.38B for Tarsus Pharmaceuticals (TARS).
Are Parabilis Medicines and Tarsus Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Parabilis Medicines and Biotechnology: Biological Products (No Diagnostic Substances) for Tarsus Pharmaceuticals.